Patients without progressive disease following induction therapy were randomised ( 1:1 ratio , using a minimisation method with biased-coin assignment balancing on ECOG performance status [ 0 vs 1 ] , response to induction chemoradiotherapy [ complete response plus near complete response vs partial response and stable disease ] , and institution ) to receive either three further cycles of consolidation etoposide plus cisplatin or irinotecan plus cisplatin ( intravenous irinotecan 60 mg/m ( 2 ) on days 1 , 8 , 15 ; intravenous cisplatin 60 mg/m ( 2 ) on day 1 ) .